Clinical Outcomes Depending on Sympathetic Innervation in Pancreatic Cancer
Cancers · 02.06.2023 · 15 (11) · 3040
DOI: 10.3390/cancers15113040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 02.06.2023. Verfasst von Elena-Anca Târtea und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy of Craiova, Romania.
Abstract (Originalsprache)
Background
The aim of our study was to evaluate sympathetic neuronal remodeling in patients with pancreatic cancer, together with its correlation with clinical outcomes.
Methods
In this descriptive, retrospective study, we analyzed pancreatic cancer specimens and peritumoral pancreatic tissue from 122 patients. We also investigated tyrosine hydroxylase immunoreactivity for the analysis of sympathetic nerve fibers and beta 2 adrenoreceptors immunoreactivity. To investigate the potential interaction between tyrosine hydroxylase (TH), beta 2 adrenoreceptors (B2A) immunoreactivity, and clinicopathological outcomes, we used the median to classify each case as TH+, respectively, B2A+ (if it presented a value higher than the median).
Results
Firstly, the overall survival was analyzed according to TH and B2A immunoreactivity, in both intratumoral and peritumoral tissue. Only B2A immunoreactivity in the peritumoral pancreatic tissue influenced overall survival at 5 years of follow-up; thus, B2A+ patients recorded a 5-year survival of only 3% compared to B2A− patients who recorded an overall survival at 5 years of follow-up of 14% (HR = 1.758, 95% CI of ratio 1.297 to 2.938, p = 0.0004). Additionally, the increased immunoreactivity of B2A in the peritumoral tissue was also associated with other factors of poor prognosis, such as moderately or poorly differentiated tumors, the absence of response to first-line chemotherapy, or metastatic disease.
Conclusions
The increased immunoreactivity of beta 2 adrenoreceptors in pancreatic peritumoral tissue represents a poor prognostic factor in pancreatic cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Psychiatry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Pathology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Oncology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
ORCID-Profile: Viorel Biciușcă, Ana-Maria Ciurea
Förderung
- University of Medicine and Pharmacy of Craiova, Romania
Zitieren
APA
Târtea, E. A., Petrescu, M., Udriștoiu, I., Gheorman, V., Biciușcă, V., Petrescu, A. R., Ciurea, A. M., & Vere, C. C. (2023). Clinical Outcomes Depending on Sympathetic Innervation in Pancreatic Cancer. Cancers, 15(11), 3040. https://doi.org/10.3390/cancers15113040
Vancouver
Târtea EA, Petrescu M, Udriștoiu I, Gheorman V, Biciușcă V, Petrescu AR, et al. Clinical Outcomes Depending on Sympathetic Innervation in Pancreatic Cancer. Cancers. 2023;15(11):3040. doi:10.3390/cancers15113040
BibTeX
@article{Trtea2023,
author = {Târtea, Elena-Anca and Petrescu, Mihai and Udriștoiu, Ion and Gheorman, Victor and Biciușcă, Viorel and Petrescu, Alexandra-Roxana and Ciurea, Ana-Maria and Vere, Cristin Constantin},
title = {Clinical Outcomes Depending on Sympathetic Innervation in Pancreatic Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {11},
pages = {3040},
doi = {10.3390/cancers15113040}
}
EUVIMED